Infectious Disease and Microbiology: HIV Infection




Human immunodeficiency virus (HIV) infection is a chronic viral disease that progressively impairs the immune system, primarily through destruction and dysfunction of CD4+ T lymphocytes. Without treatment, it can lead to acquired immunodeficiency syndrome (AIDS), the advanced stage of infection characterized by severe immunosuppression, opportunistic infections, malignancies, and death. HIV-1 is the predominant type worldwide, while HIV-2 is found mainly in West Africa and generally causes slower disease progression.


HIV remains a major global health problem, affecting millions of individuals worldwide. In the United States alone, more than one million people are living with HIV, with tens of thousands of new infections occurring annually. Transmission occurs through sexual contact, blood exposure such as needle-sharing or occupational exposure, and mother-to-child transmission during pregnancy, delivery, or breastfeeding. The risk of transmission varies by route, with blood exposure and receptive anal intercourse carrying higher risks than other exposures. Advances in antiretroviral therapy (ART) and perinatal management have markedly reduced maternal–fetal transmission.


The virus is a retrovirus of the lentivirus family. It binds to CD4 receptors and co-receptors on host lymphocytes, enters the cell, and uses reverse transcriptase to convert viral RNA into DNA. This viral DNA integrates into the host genome, allowing lifelong infection. Subsequent activation of infected cells leads to production of new viral particles, which destroy CD4 cells and gradually weaken cellular immunity. This immune dysfunction predisposes patients to a wide range of infectious and noninfectious complications.


Clinically, HIV infection progresses through several stages. Acute HIV infection may occur within weeks of transmission and often presents with a nonspecific viral syndrome including fever, pharyngitis, rash, myalgias, lymphadenopathy, diarrhea, and headache. This is followed by an asymptomatic phase that may last many years, during which viral replication continues and CD4 counts slowly decline. Symptomatic HIV infection develops as immunosuppression worsens and may include recurrent mucocutaneous infections, weight loss, fevers, and eventually opportunistic infections such as Pneumocystis jirovecii pneumonia, cryptococcal meningitis, toxoplasmosis, cytomegalovirus disease, and Mycobacterium avium complex infection. HIV is also associated with malignancies such as Kaposi sarcoma, lymphoma, cervical cancer, and neurologic complications including HIV-associated neurocognitive disorder.


Diagnosis begins with screening using highly sensitive HIV antibody tests, followed by confirmatory testing. In suspected acute HIV infection, HIV RNA testing is essential because antibody tests may still be negative during early infection. Once diagnosis is confirmed, baseline evaluation includes CD4 count, HIV viral load, resistance genotype, complete blood count, renal and liver function tests, and screening for co-infections such as hepatitis A, B, and C, syphilis, tuberculosis, toxoplasmosis, cytomegalovirus, and varicella zoster. These tests help assess disease stage, identify treatment needs, and detect concurrent infections.


Treatment with antiretroviral therapy is the cornerstone of HIV management. The goals of ART are to suppress plasma HIV RNA to undetectable levels, preserve or restore immune function, reduce HIV-related complications, and prevent transmission. Standard treatment consists of combination therapy using multiple drug classes, commonly two nucleos(t)ide reverse transcriptase inhibitors together with either a non-nucleoside reverse transcriptase inhibitor, a protease inhibitor, or an integrase strand transfer inhibitor. Choice of regimen depends on drug resistance, side effects, pill burden, co-morbidities, pregnancy considerations, and potential drug interactions. ART is generally lifelong, and adherence is critical to prevent virologic failure and resistance.


Prevention of HIV includes condom use, safe blood practices, clean needle access, screening of blood products, and routine testing, especially in pregnancy and high-risk populations. Post-exposure prophylaxis should be started as soon as possible after significant occupational or non-occupational exposure, ideally within hours and no later than 72 hours, and continued for four weeks. Pre-exposure prophylaxis has also become an important preventive strategy for individuals at substantial risk.


Ongoing care requires regular monitoring of viral load, CD4 count, medication toxicity, cardiovascular risk factors, and co-infections. Patients with advanced immunosuppression require prophylaxis against opportunistic infections, such as trimethoprim-sulfamethoxazole for Pneumocystis and toxoplasmosis, and azithromycin for Mycobacterium avium complex when indicated. Vaccination, cancer screening, and management of long-term complications are also essential parts of care.


The prognosis of HIV infection has improved dramatically with effective ART. Many patients who are diagnosed early and remain adherent to treatment can achieve near-normal life expectancy. However, treatment failure may occur due to poor adherence or drug resistance, leading to virologic, immunologic, and clinical decline. Without treatment, HIV infection remains a progressive and often fatal disease.

​

Emergency and Acute Medicine – Wheezing




Wheezing is a high-pitched, musical sound produced by turbulent airflow through narrowed airways, typically with a dominant frequency around 400 Hz. It occurs when airflow causes vibration of bronchial walls, similar to a reed instrument. Wheezing is most prominent when airway diameters are between 2–5 mm; larger airways produce lower-pitched sounds, while very small airways (<2 mm) may not transmit sound effectively due to energy loss. Airway narrowing may result from bronchoconstriction, inflammation, edema, or obstruction, and identifying the underlying mechanism is critical in acute care settings.


The causes of wheezing are broad and include both small-airway (pulmonary) and large-airway etiologies. Small-airway causes commonly include Asthma, Chronic Obstructive Pulmonary Disease, pulmonary edema, anaphylaxis, and aspiration. Certain drugs such as ACE inhibitors, β-blockers, aspirin, and NSAIDs may precipitate bronchospasm or allergic reactions. Less common causes include pulmonary embolism, carcinoid tumors, and occupational lung diseases like byssinosis. Large-airway causes include foreign body aspiration, vocal cord dysfunction, epiglottitis, tumors, and smoke inhalation. In pediatric populations, common causes include Bronchiolitis, asthma, croup, and congenital airway abnormalities such as tracheomalacia.


Clinically, wheezing presents as a whistling sound during breathing, often accompanied by dyspnea, cough, chest tightness, and respiratory distress. Diffuse wheezing suggests generalized airway disease such as asthma or pulmonary edema, while focal wheezing raises concern for localized obstruction such as pneumonia or foreign body. Associated findings may include tachypnea, tachycardia, cyanosis, and use of accessory muscles. A critical aspect of assessment is the patient’s mental status—fatigue, confusion, or lethargy may indicate impending respiratory failure and necessitate urgent airway management.


Evaluation begins with assessment of severity and oxygenation. Pulse oximetry is essential for monitoring oxygen saturation, while peak expiratory flow (PEF) helps quantify airway obstruction and response to treatment. Chest X-ray may be used to evaluate for pneumonia, pulmonary edema, or foreign body. Arterial blood gas (ABG) may be useful in severe cases to assess for rising CO₂ and acidosis, indicating respiratory fatigue. Additional investigations such as ECG or laryngoscopy may be indicated depending on suspected etiology.


Management focuses on rapid stabilization and reversal of airway obstruction. Initial treatment includes supplemental oxygen and airway support. Bronchodilators are first-line therapy, particularly Albuterol given as 2.5–5 mg nebulized every 20 minutes for 3 doses (pediatric: 0.15 mg/kg per dose, minimum 2.5 mg). Systemic corticosteroids such as Prednisone (40–80 mg PO; pediatric 1 mg/kg/day, max 60 mg) or Methylprednisolone (40–80 mg IV) are used to reduce airway inflammation and prevent relapse.


For moderate to severe cases, Ipratropium Bromide (0.5 mg nebulized every 20 minutes for 3 doses) can be added to β-agonist therapy. Additional therapies include magnesium sulfate (0.1 mL/kg of 50% solution IV over 20 minutes) in severe asthma, terbutaline (0.25 mg SC), and heliox in selected cases. In pediatric croup, racemic epinephrine (0.25–0.5 mL nebulized) may be used. Intubation is indicated for patients with impending respiratory failure, and Ketamine may be preferred due to its bronchodilatory properties.


Disposition depends on clinical response. Patients with persistent hypoxia, worsening symptoms, or underlying serious conditions require admission. Those who improve with treatment, achieve PEF >70% predicted, and maintain adequate oxygenation may be discharged with follow-up and clear return precautions. Patients with asthma should receive an action plan and appropriate outpatient referral.


A key clinical pearl is to always consider non-asthma causes of wheezing, especially in cases of focal findings or poor response to bronchodilators. Additionally, clinicians must be prepared for rapid airway deterioration, particularly when administering sedatives or managing severe respiratory distress.

​

Emergency and Acute Medicine – Alcohol Withdrawal




Alcohol Withdrawal is the most common withdrawal syndrome encountered in the emergency department and represents a spectrum of neuroexcitatory symptoms that occur after cessation or reduction of chronic alcohol use. The underlying mechanism involves neuroadaptation: chronic alcohol exposure enhances inhibitory GABA activity and suppresses excitatory NMDA receptors. When alcohol intake stops, this balance shifts toward excess excitation, leading to autonomic hyperactivity and neurologic symptoms. Repeated withdrawal episodes may worsen severity through a process known as kindling, increasing the risk of life-threatening complications.


Alcohol withdrawal progresses through a predictable timeline with four major clinical stages. Early withdrawal begins within 6–8 hours after the last drink and lasts 1–2 days, presenting with tremulousness, anxiety, palpitations, nausea, and anorexia. Withdrawal seizures typically occur between 6–48 hours and are usually brief, generalized seizures. Alcoholic hallucinosis develops within 12–48 hours and is characterized by visual (most common), tactile, or auditory hallucinations, often with a relatively clear sensorium. The most severe form, delirium tremens (DTs), occurs 48–96 hours after cessation and may last up to 5 days, presenting with tachycardia, hypertension, diaphoresis, agitation, and delirium. DTs occur in approximately 5% of patients but carry a high mortality rate of 5–15%.


Diagnosis is primarily clinical, based on history and physical examination. Key historical features include the time of last alcohol intake, history of prior withdrawal episodes, and severity of previous symptoms. Physical examination should focus on vital signs and signs of autonomic instability. Laboratory evaluation typically includes electrolytes, renal function, glucose, magnesium, CBC, and blood alcohol level, as well as screening for coexisting conditions such as infection. Imaging such as CT of the head is reserved for patients with altered mental status or unclear diagnosis.


Management begins with initial stabilization, including airway, breathing, and circulation, IV access, fluid resuscitation, and continuous monitoring. The cornerstone of treatment is benzodiazepines, which act by enhancing GABA activity and reducing CNS hyperexcitability. Commonly used agents include Diazepam (5–10 mg IV, repeat as needed; 5–20 mg PO for mild symptoms) and Lorazepam (2 mg IV or PO every 2–4 hours as needed). High or repeated dosing is often required to adequately control symptoms.


In severe or refractory cases, adjunctive therapies such as Phenobarbital (15–20 mg/kg IV for severe symptoms or status epilepticus) or Propofol (25–75 μg/kg/min infusion) may be used, particularly in ICU settings. Supportive care includes correction of electrolyte abnormalities and monitoring for complications such as arrhythmias or aspiration.


Disposition depends on severity. Patients with moderate-to-severe withdrawal, persistent symptoms, delirium tremens, or significant comorbidities require hospital admission, often to a monitored or intensive care setting. Patients with mild symptoms that respond well to therapy may be discharged with close follow-up and referral to a detoxification program.


A key clinical pearl is to avoid under-treatment with benzodiazepines, as inadequate dosing can lead to progression to severe withdrawal or DTs. Additionally, clinicians must remain vigilant for alternative diagnoses, as medical conditions such as infection, hypoglycemia, or intracranial pathology may mimic or coexist with alcohol withdrawal.

​

Emergency and Acute Medicine – Drug Withdrawal




Drug Withdrawal refers to the constellation of symptoms that occur when a substance that has been used chronically is abruptly reduced or discontinued. The hallmark of many withdrawal syndromes—particularly those involving benzodiazepines, barbiturates, and opioids—is neuroexcitation, resulting from adaptive changes in the central nervous system. While withdrawal from sedative-hypnotics such as benzodiazepines and barbiturates can be life-threatening, opioid withdrawal is typically not fatal but can be extremely uncomfortable. Withdrawal from stimulants such as cocaine and amphetamines is also generally not life-threatening but can cause significant psychological distress.


The pathophysiology involves neuroadaptation to chronic drug exposure. With prolonged use, the body adjusts to the presence of the substance, leading to tolerance, where increasing doses are needed to achieve the same effect. When the drug is removed, these adaptations persist, resulting in withdrawal symptoms. It is important to distinguish tolerance from withdrawal, as they are related but separate phenomena.


Clinical features vary depending on the substance. Benzodiazepine and barbiturate withdrawal presents with anxiety, agitation, tremor, insomnia, tachycardia, hypertension, hyperthermia, and autonomic instability, with the potential for seizures and life-threatening complications. Opioid withdrawal is characterized by restlessness, irritability, drug craving, yawning, piloerection (“goosebumps”), mydriasis, nausea, vomiting, diarrhea, abdominal pain, tachycardia, and hypertension. Cocaine withdrawal typically manifests with depressed mood, fatigue, vivid dreams, sleep disturbances, and psychomotor changes, while amphetamine withdrawal presents with fatigue, irritability, anxiety, and sleep disturbances.


Diagnosis is primarily clinical and relies on a detailed substance use history, including the type of drug, time of last use, and any previous withdrawal episodes. Physical examination focuses on vital signs and signs of autonomic instability. Laboratory testing (electrolytes, renal function, glucose, CBC) may be helpful to identify complications or alternative diagnoses, although urine drug screening rarely changes acute management. Imaging is reserved for cases where the diagnosis is unclear or other pathology is suspected.


Management begins with initial stabilization, including airway, breathing, and circulation, IV access, fluid resuscitation, and monitoring. Treatment is then tailored to the specific withdrawal syndrome. For benzodiazepine or barbiturate withdrawal, aggressive supportive care and substitution with a long-acting agent of the same class are recommended, using medications such as Diazepam (5–10 mg IV repeated as needed; 5–20 mg PO for mild symptoms) or Lorazepam (1–2 mg PO or 2 mg IV repeated as needed). Severe cases or seizures may require Phenobarbital (15–20 mg/kg IV).


In opioid withdrawal, treatment is largely supportive. Symptom control includes antiemetics such as Ondansetron (4–8 mg PO/IV) and autonomic symptom relief with Clonidine (0.1–0.3 mg PO every 4–6 hours). Opioid replacement therapy may be considered in certain cases, especially when withdrawal complicates other medical conditions. For cocaine and amphetamine withdrawal, management is supportive, focusing on rest, hydration, and monitoring for psychiatric symptoms.


Disposition depends on severity and associated risks. Patients with moderate-to-severe symptoms, persistent withdrawal, psychosis, autonomic instability, or significant comorbid conditions require admission. Those with mild symptoms who respond to therapy and are psychiatrically stable may be discharged with appropriate follow-up. Referral to a detoxification or rehabilitation program is essential for long-term management.


A key clinical pearl is to avoid misdiagnosing other serious medical conditions as withdrawal, as infections, metabolic disturbances, or intracranial pathology may mimic withdrawal syndromes. Additionally, clinicians should ensure adequate dosing of benzodiazepines in sedative withdrawal, as under-treatment can lead to severe complications, including seizures.

​

​Emergency and Acute Medicine – Wolff–Parkinson–White (WPW) Syndrome


Wolff–Parkinson–White syndrome (WPW) is a cardiac conduction disorder caused by the presence of an accessory pathway (Kent bundle) that bypasses the atrioventricular (AV) node, allowing premature ventricular activation (pre-excitation). On ECG, the WPW pattern is characterized by a short PR interval (<0.12 sec), a delta (Δ) wave representing early ventricular depolarization, and a widened QRS complex (>0.10 sec). While the ECG pattern alone is termed WPW pattern, the diagnosis of WPW syndrome requires both these findings and associated tachydysrhythmias.


Accessory pathways occur in approximately 0.1–0.3% of the population and are most commonly located along the left lateral free wall, followed by the posteroseptal region. Conduction through these pathways may occur in antegrade, retrograde, or bidirectional fashion. The most common arrhythmia associated with WPW is orthodromic atrioventricular re-entrant tachycardia (AVRT) (≈70%), where impulses travel down the AV node and return via the accessory pathway, producing a narrow complex tachycardia. Less commonly, antidromic AVRT (≈30%) occurs, with conduction down the accessory pathway and back through the AV node, resulting in a wide complex tachycardia. WPW can also precipitate atrial fibrillation with rapid ventricular response, which carries a risk of degeneration into ventricular fibrillation and sudden death.


Patients may be asymptomatic or present with palpitations, chest pain, dyspnea, dizziness, diaphoresis, or syncope. Physical findings depend on the rhythm and hemodynamic status, ranging from stable tachycardia to signs of instability such as hypotension, altered mental status, cyanosis, or pulmonary edema. Sudden cardiac death is rare but can occur (approximately 1 per 1,000 patient-years).


Diagnosis is based primarily on ECG findings. During sinus rhythm, the classic triad includes short PR interval, delta wave, and widened QRS complex. During tachyarrhythmias, ECG patterns vary depending on the mechanism: orthodromic AVRT typically produces a narrow complex tachycardia (150–250 bpm), while antidromic AVRT produces a wide complex tachycardia. Atrial fibrillation in WPW appears as an irregular wide complex rhythm with variable QRS morphology, which is a dangerous presentation.


Management depends on patient stability and rhythm type. Unstable patients (hypotension, chest pain, altered mental status) require immediate synchronized cardioversion, starting at 100 J and escalating as needed. In stable patients, initial management includes vagal maneuvers such as the Valsalva maneuver or carotid sinus massage (if no contraindications).


For narrow complex tachycardia (orthodromic AVRT), pharmacologic therapy includes Adenosine (6 mg rapid IV bolus, followed by 12 mg if needed; pediatric: 0.1–0.2 mg/kg) or calcium channel blockers when the diagnosis is certain. For wide complex tachycardia or suspected WPW with atrial fibrillation, Amiodarone (150 mg IV over 10 minutes, followed by infusion) or Procainamide (6–13 mg/kg IV infusion) are preferred.


Critically important: AV nodal–blocking agents such as β-blockers, calcium channel blockers, digoxin, and lidocaine must be avoided in patients with WPW and wide complex tachycardia or atrial fibrillation, as they may enhance conduction through the accessory pathway and precipitate fatal ventricular arrhythmias.


Disposition depends on clinical presentation. Patients with instability, syncope, or refractory arrhythmias require admission and monitoring. Most stable patients who convert to sinus rhythm can be discharged with cardiology follow-up, including consideration of electrophysiologic studies and radiofrequency ablation, which offers definitive treatment.


Key clinical pearls include maintaining a high suspicion for WPW in any tachydysrhythmia, avoiding AV nodal blockers in uncertain wide complex rhythms, and addressing anticoagulation if arrhythmia duration exceeds 48 hours due to embolic risk.

Infectious Disease and Microbiology: Herpes Zoster (Shingles)




Herpes zoster, commonly known as shingles, is a localized skin and nerve infection caused by reactivation of the Varicella zoster virus, the same virus responsible for chickenpox. After a primary infection, the virus remains dormant in sensory nerve ganglia for years. Reactivation later in life leads to herpes zoster, typically presenting as a painful, vesicular rash confined to a specific dermatome.


Epidemiologically, herpes zoster occurs worldwide and affects approximately 20% of individuals during their lifetime. The incidence increases significantly with age, particularly in those over 50 years. Nearly 90% of adults have evidence of prior VZV infection, placing them at risk for reactivation. Immunocompromised individuals—such as those with HIV infection, malignancies, or those receiving immunosuppressive therapy—are at particularly high risk and may develop more severe or disseminated disease.


The pathophysiology involves reactivation of latent virus within dorsal root or cranial nerve ganglia. The virus travels along sensory nerves to the skin, producing inflammation and the characteristic painful rash. The exact triggers for reactivation are not fully understood but are strongly associated with declining cell-mediated immunity, especially in aging or immunosuppressed individuals.


Clinically, patients typically present with localized pain, burning, or tingling in a dermatomal distribution, often preceding the rash by a few days. This is followed by the appearance of grouped vesicles on an erythematous base, usually confined to one side of the body. The thoracic and lumbar dermatomes are most commonly affected. Involvement of the trigeminal nerve may lead to ocular complications (herpes zoster ophthalmicus), while involvement of the geniculate ganglion can result in Ramsay Hunt syndrome, characterized by ear lesions and facial paralysis.


Diagnosis is primarily clinical, based on the typical unilateral dermatomal rash and associated pain. Laboratory tests such as PCR or serology can confirm the diagnosis but are rarely necessary in routine cases. Imaging or lumbar puncture may be required if central nervous system involvement is suspected.


Treatment focuses on antiviral therapy and pain management. First-line therapy includes oral acyclovir, while alternatives such as valacyclovir or famciclovir offer improved dosing convenience. In severe cases or immunocompromised patients, intravenous antivirals may be required. Adjunctive therapies, including analgesics and sometimes corticosteroids, may help reduce acute symptoms, although steroids do not prevent long-term complications.


The prognosis is generally good in immunocompetent individuals, but complications are not uncommon. The most significant is postherpetic neuralgia, a chronic pain condition that can persist long after the rash resolves, particularly in older adults. Other complications include secondary bacterial infection, ocular damage potentially leading to blindness, and, in severe cases, systemic involvement such as pneumonitis, hepatitis, or central nervous system disease.


Prevention includes vaccination against VZV, which reduces both the incidence of herpes zoster and the risk of postherpetic neuralgia. In high-risk individuals, prophylactic antivirals or immunoglobulin may be used following exposure.

​

Infectious Disease and Microbiology: Histoplasmosis




Histoplasmosis is an inhalation-acquired fungal infection primarily affecting the lungs and caused by the dimorphic fungus Histoplasma capsulatum. It is an endemic mycosis, meaning it occurs in specific geographic regions, and infection typically follows inhalation of fungal spores from contaminated environments such as soil enriched with bird or bat droppings.


Epidemiologically, histoplasmosis is most common in areas such as the Ohio and Mississippi River valleys in the United States, with hundreds of thousands of infections occurring annually. Although both sexes are equally exposed, disseminated disease is more common in males. Individuals at highest risk include infants, older adults, and especially immunocompromised patients, such as those with HIV/AIDS, malignancies, organ transplants, or those receiving immunosuppressive therapies.


The pathophysiology begins when microconidia (infectious spores) are inhaled into the lungs. Inside the host, the organism converts from its mold form to a yeast form and multiplies within macrophages. This intracellular survival allows the fungus to spread through the reticuloendothelial system. While most infections remain localized and asymptomatic, impaired immunity can lead to widespread dissemination affecting multiple organs.


Clinically, histoplasmosis presents in several forms. Acute pulmonary histoplasmosis is often asymptomatic or presents as a mild flu-like illness with fever, cough, chest pain, and malaise. Chronic pulmonary histoplasmosis, typically seen in older individuals with underlying lung disease, resembles tuberculosis with symptoms such as chronic cough, weight loss, night sweats, and hemoptysis. Disseminated histoplasmosis is the most severe form, particularly in immunocompromised patients, and may involve fever, hepatosplenomegaly, skin lesions, adrenal insufficiency, or even central nervous system involvement.


Physical examination findings vary depending on the form of disease but may include enlarged liver and spleen, skin eruptions, or mucosal ulcers in disseminated disease. Pulmonary findings such as crackles or signs of consolidation may also be present. In some cases, complications such as mediastinal fibrosis or pericarditis can occur due to lymph node involvement.


Diagnosis is established through a combination of laboratory and imaging studies. Detection of Histoplasma antigen in urine or serum is highly sensitive, especially in disseminated disease. Fungal cultures can confirm the diagnosis but may take several weeks. Serologic tests, PCR, and histopathological examination of tissue samples showing granulomas with yeast forms are also useful. Imaging studies, such as chest X-rays or CT scans, may reveal pulmonary infiltrates, nodules, calcifications, or lymphadenopathy.


Treatment depends on disease severity. Mild acute pulmonary histoplasmosis often requires no treatment and resolves spontaneously. More severe or persistent cases are treated with antifungal agents such as itraconazole. Severe or disseminated disease requires initial therapy with amphotericin B followed by prolonged itraconazole therapy. Immunocompromised patients may require long-term suppressive therapy to prevent relapse.


The prognosis of histoplasmosis is generally good in mild cases but can be life-threatening in disseminated disease, particularly in immunosuppressed individuals. Complications include chronic lung damage, adrenal insufficiency, mediastinal fibrosis, and, in severe cases, respiratory failure or death. Early recognition and appropriate antifungal therapy are critical in improving outcomes.

​

Infectious Disease and Microbiology: Intraabdominal Abscess




An intraabdominal abscess is a localized collection of microorganisms, inflammatory cells, and pus enclosed within a fibrous capsule in the abdominal cavity. These abscesses may form within the peritoneal cavity, inside abdominal organs such as the liver or spleen, or in retroperitoneal spaces. They can also extend into adjacent areas like the pelvis or psoas muscle. Based on location, intraabdominal abscesses are classified as intraperitoneal, visceral, or retroperitoneal.


Epidemiologically, intraabdominal abscesses are more common in men and typically occur between the third and fifth decades of life. Most abscesses are located in intraperitoneal or retroperitoneal spaces rather than within organs. Common causes vary by age group and condition; for example, appendicitis is a major cause in children, while postoperative complications are more common in adults. Patients with diabetes, immunosuppression, malignancy, or conditions like pancreatitis are at increased risk. Certain infections, including fungal infections such as Candida, may occur more frequently in immunocompromised individuals.


The pathophysiology usually involves the دخول of enteric organisms into the peritoneal cavity through disruption of the gastrointestinal tract, such as perforation, inflammation, trauma, or surgery. This leads to localized infection, inflammation, and abscess formation. Both aerobic and anaerobic bacteria often act synergistically. Common causative organisms include Bacteroides fragilis, Enterobacteriaceae (such as Escherichia coli), streptococci, enterococci, and sometimes fungi like Candida. The exact pathogens depend on the source and location of the infection.


Clinically, patients often present with nonspecific symptoms such as fever, abdominal pain, nausea, vomiting, malaise, and sometimes signs of sepsis. The presentation varies depending on the location of the abscess. Liver abscesses may cause right upper quadrant pain and systemic symptoms, while splenic abscesses may present with left upper quadrant pain. Perinephric abscesses often cause flank pain that may radiate to the groin. In elderly patients, fever of unknown origin may be the only presenting sign, making diagnosis challenging.


Diagnosis relies on a high index of suspicion and appropriate investigations. Laboratory findings may include leukocytosis, abnormal liver function tests, anemia, and sometimes bacteremia. Imaging plays a crucial role, with computed tomography (CT) scan being the most sensitive and widely used modality. Ultrasound is also useful, especially for liver and kidney abscesses. Definitive diagnosis is often achieved by aspiration of abscess contents for microbiological analysis, which helps guide targeted antimicrobial therapy.


Management of intraabdominal abscesses involves three key components: control of the source of infection, administration of appropriate antimicrobial therapy, and drainage of the abscess. Broad-spectrum antibiotics are initiated empirically and later tailored based on culture results. Common regimens include combinations that cover both aerobic and anaerobic organisms, such as cephalosporins with metronidazole, carbapenems, or beta-lactam/beta-lactamase inhibitor combinations. Antifungal therapy is indicated when fungal pathogens are identified.


Drainage of the abscess is essential and can be achieved either percutaneously under imaging guidance or surgically. Percutaneous drainage is preferred when feasible, but surgical intervention is required in cases where drainage is not possible, the abscess is multiloculated, or there is failure to respond to conservative treatment. Some cases, such as small or specific types of abscesses, may be managed medically under close monitoring.


Patients with severe infection may require hospitalization, fluid resuscitation, and intensive care support if septic shock develops. Ongoing care includes close monitoring, follow-up imaging, and addressing underlying conditions such as biliary disease, malignancy, or urinary tract abnormalities. Preventive strategies focus on early diagnosis and management of intraabdominal infections and prompt treatment of conditions like appendicitis or diverticulitis.


The prognosis depends on early recognition and effective management. Mortality rates remain significant, particularly for splenic and hepatic abscesses, especially if diagnosis is delayed. Prompt treatment with antibiotics and adequate drainage significantly improves outcomes.

​

Infectious Disease and Microbiology: Influenza




Influenza is an acute viral respiratory infection caused by influenza viruses, typically presenting as a self-limited illness but capable of causing severe or life-threatening complications in vulnerable populations. While most healthy individuals recover fully, high-risk groups—including the elderly, young children, pregnant women, and those with chronic medical conditions—are more likely to develop complications such as pneumonia, respiratory failure, or death.


Influenza is highly prevalent worldwide, affecting approximately 5–20% of the population annually. Seasonal outbreaks occur predominantly during the winter months, often referred to as “flu season.” In the United States, influenza is responsible for tens of thousands of deaths and hundreds of thousands of hospitalizations each year. Occasionally, pandemics arise when new subtypes of influenza A viruses emerge, often due to major genetic changes, allowing rapid global spread with little preexisting immunity in the population.


Transmission occurs through respiratory droplets, direct contact with infected individuals, or contaminated surfaces. Viral shedding begins early—often within the first day of infection—and continues for about 5–10 days, though children may shed the virus longer. Preventive measures include good hand hygiene, respiratory etiquette, and especially annual vaccination. Vaccination is recommended for all individuals older than 6 months, with particular emphasis on high-risk groups. Two main vaccine types are available: inactivated vaccines given intramuscularly and live attenuated vaccines administered intranasally.


Influenza viruses are RNA viruses belonging to the Orthomyxoviridae family and are classified into types A, B, and C. Types A and B are responsible for most seasonal epidemics, while type C typically causes mild disease. Influenza A viruses are further subtyped based on hemagglutinin (HA) and neuraminidase (NA) surface proteins. Antigenic drift (small mutations) leads to seasonal variation, whereas antigenic shift (major genetic reassortment) can result in pandemics. The virus infects respiratory epithelial cells, and symptoms are largely due to the host immune response, including the release of proinflammatory cytokines, which may lead to severe complications such as cytokine storm and multiorgan failure.


Clinically, influenza is characterized by abrupt onset of fever, cough, nasal congestion, myalgia, headache, and malaise. The sudden onset of fever and cough during influenza season is highly suggestive of the disease. In some cases, especially in high-risk individuals, complications such as bacterial pneumonia may develop several days after initial symptoms, often indicated by recurrence of fever and worsening respiratory symptoms. Severe cases may involve exacerbation of underlying conditions like asthma or heart failure, as well as rare complications such as encephalitis, myocarditis, rhabdomyolysis, or shock.


Diagnosis is confirmed through laboratory testing of respiratory specimens. Reverse transcription polymerase chain reaction (RT-PCR) is the most sensitive and specific test and provides rapid results. Rapid antigen tests are also available but are less sensitive, especially in adults. Imaging such as chest X-ray may be necessary in severe cases to assess for pneumonia or other complications.


Treatment includes antiviral medications and supportive care. Neuraminidase inhibitors such as Oseltamivir and Zanamivir are effective against both influenza A and B and are most beneficial when started within 48 hours of symptom onset. They are especially recommended for high-risk patients or those with severe disease. Older drugs such as amantadine and rimantadine are less commonly used due to resistance. Supportive care includes rest, hydration, and management of symptoms.


In hospitalized patients, severe influenza may require intensive care support, including oxygen therapy, mechanical ventilation, or extracorporeal membrane oxygenation in cases of respiratory failure. Early antiviral treatment is recommended for hospitalized patients regardless of the duration of symptoms.


The prognosis for most individuals is good, with complete recovery expected. However, influenza can lead to serious complications, particularly in high-risk groups. These include bacterial pneumonia (commonly due to Streptococcus pneumoniae), acute respiratory distress syndrome (ARDS), myocarditis, and neurologic complications such as encephalopathy or Guillain–Barré syndrome. Vaccination and early treatment remain key strategies in reducing morbidity and mortality associated with influenza.

​

Infectious Disease and Microbiology: Infectious Mononucleosis




Infectious mononucleosis (IM), also known as glandular fever, is a common self-limiting clinical syndrome caused primarily by Epstein–Barr virus. It is characterized by acute onset of fever, sore throat, lymphadenopathy, and atypical lymphocytosis. EBV is transmitted mainly through saliva, which is why the illness is often called the “kissing disease.” After infection, the virus persists lifelong in the host.


IM is common worldwide. In industrialized countries, EBV infection often occurs either in early childhood, when it is usually asymptomatic, or in late adolescence, when it is more likely to cause symptomatic mononucleosis. By adulthood, 90–95% of people have evidence of prior EBV infection. Risk factors include close contact with an infected person and immunosuppression, especially in transplant recipients. In rare cases, certain inherited immune defects can lead to severe, even life-threatening EBV infection.


The pathophysiology begins when EBV infects the oropharyngeal epithelium and then B lymphocytes. The immune response, especially proliferation of cytotoxic CD8+ T lymphocytes, is responsible for much of the clinical syndrome. These activated lymphocytes appear as atypical lymphocytes on the blood smear. Although the immune response controls the primary infection, EBV remains latent for life.


Clinically, young children are often asymptomatic or have only mild illness. In adolescents and young adults, the disease usually begins with fatigue, malaise, and myalgias, followed by fever and sore throat. Common symptoms include fever, sore throat, malaise, headache, anorexia, myalgias, and sometimes abdominal pain, nausea, or vomiting. On examination, patients commonly have cervical lymphadenopathy, pharyngitis or tonsillitis, splenomegaly, and sometimes hepatomegaly. Less common findings include palatal petechiae, periorbital edema, rash, and jaundice. A maculopapular rash may occur, especially after exposure to ampicillin or amoxicillin.


Diagnosis is usually supported by laboratory findings. Atypical lymphocytosis and relative or absolute lymphocytosis are common. Mild thrombocytopenia and elevated liver enzymes may also be present. Heterophile antibody tests such as the Monospot are widely used and are fairly sensitive and specific in symptomatic patients, although they may be negative early in illness or in young children. EBV-specific serology, including viral capsid antigen and EBV nuclear antigen antibodies, can help confirm the diagnosis when needed. Ultrasound may be used to assess splenomegaly, especially in athletes.


Treatment is mainly supportive. Most patients only need rest, fluids, and symptom relief with acetaminophen or nonsteroidal anti-inflammatory drugs. Corticosteroids are reserved for severe complications such as impending airway obstruction, severe thrombocytopenia, hemolytic anemia, myocarditis, pericarditis, or neurologic complications. Patients should avoid contact sports and strenuous physical activity for at least 3–4 weeks, or longer if splenomegaly persists, because of the risk of splenic rupture. Beta-lactam antibiotics such as ampicillin and amoxicillin should be avoided unless clearly indicated for another reason.


The prognosis is generally excellent, and most cases resolve within 1–2 weeks. However, fatigue may persist for weeks or even months in some patients. Complications are uncommon but may include autoimmune hemolytic anemia, thrombocytopenia, airway obstruction, hepatitis, myocarditis, pericarditis, neurologic syndromes, pneumonia, splenic rupture, and lymphoproliferative disorders in susceptible individuals.

​